NIH Reporter #75N95022D00021-P00001-759502300003-1

Solicitation for manufacturing of plasmids, vectors, and GLP toxicology studies for AGU treatment research

This opportunity is issued by the National Institute on Drug Abuse (NIDA), via Battelle Centers for Public Health Research & Evaluation, to support AGU treatment research under a cooperative agreement with the National Institute of Neurological Disorders and Stroke (NINDS). - Government Buyer: - National Institute on Drug Abuse (NIDA) - Battelle Centers for Public Health Research & Evaluation, Columbus, Ohio - OEMs and Vendors: - No specific OEMs or vendors are named in the solicitation - Products/Services Requested: - Manufacturing of plasmids and vectors for AGU research - Good Laboratory Practice (GLP) dose-escalation toxicology studies - No part numbers or quantities specified - Unique/Notable Requirements: - Strict adherence to GLP standards for toxicology studies - Focused on supporting Aspartylglucosaminuria (AGU) treatment research - Comprehensive biomanufacturing and toxicology services required - Period of Performance: - Approximately three years from project start to completion

Description

This project involves manufacturing of plasmids, vectors, and conducting GLP dose-escalation toxicology studies. It is related to a cooperative agreement funded by NINDS for the treatment of Aspartylglucosaminuria (AGU). The project duration is from September 30, 2023, to September 29, 2026. The work is under the National Institute on Drug Abuse (NIDA) and Battelle Centers for Public Health Research & Evaluation in Columbus, OH.

View original listing